Medicine in recent years has been moving in search of an approach to personalized treatments and based on the search for alternatives within the framework of molecular and genetic analysis methods.
Dr.. Omayra Reyes is a hematologist and oncologist
Marcella Moreno WelshiesLatin Agency for News Medicine and Public Health
In an interview with Journal of Medicine and Public Health (MSP), Dr. Omayra Reyes, Hematologist and Oncologist, highlights the benefit of anti-pd1 therapies in fighting cancer and highlights the importance and contributions of immunotherapy, which works to stimulate the immune system to fight cancer cells.
The specialist qualifies these treatments as advances in oncology, where immunotherapy or anti-pd1 They revolutionized cancer medicine, meaning they were able to save more years of life for patients who previously enjoyed more limited treatments.
“Mainly in the case of immunotherapy, the anti-pd1 agents brought in a new group of kidney cancer patients, which advanced, providing an increase in survival compared to what was basically the standard treatmentThe oncologist indicated.
Today, when comparing drugs years ago to current drugs, it can be seen that patients are offered a 24-month survival rate in 74 or 75% of patients.
The quality of life and side effects are also more controllable, and the toxic effects have been observed in clinical studies, while in clinical practices it has been observed that the number of patients tolerating the combination more and more is increasing. Treatments like those already approved with checkpoint inhibitors that fundamentally increase survival and stabilize the medical condition.
Inhibitor treatments do not necessarily work in combination with other treatments, but they can be used in a streak fashion to reduce the chances of toxic effects.
Benefits of pd1 inhibitors
Compared to treatments used years ago, checkpoint inhibitors have a safer side-effect profile and a patient’s response to their medical condition is more sustainable.
Within the treatment with this type of drug, Dr. Reyes also highlights the tolerability of these drugs, and a profile of safe side effects, highlighting that the response properties they provide, especially, increase the survival of all cancer patients. Who uses it.